Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Safety Trial in Metastatic Renal Cell Carcinoma (NIVOREN)
NCT03013335Phase 2Completed
- Sponsor
- Unicancer
- Start
- Jan 2016
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in metastatic renal cell carcinoma (mRCC), sponsored by Unicancer. Started Jan 2016; status: completed.
02
Drugs
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT03013335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03013335.